The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements, and were granted as an inducement ...

A new study by researchers at Intermountain Health in Salt Lake City finds that 40 percent of newly diagnosed heart failure patients also have atrial fibrillation – a combination of cardiac disorders ...

results were presented from the SUMMIT trial (NCT04847557), which evaluated the impact of Eli Lilly’s tirzepatide in patients ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

According to research conducted by Johns Hopkins University, a form of heart failure known as heart failure with a preserved ejection fraction or HFpEF is responsible for more than half of all heart ...

Detailed results were announced from a phase 3 clinical trial evaluating the use of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The multicenter, ...

The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

Here are eight takeaways from the study: The study included 731 heart failure patients with an ejection fraction of at least 50% and a body-mass index of at least 30. Of the participants 364 received ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half ...